Cuorips Inc.
4894・Growth Market・Pharmaceuticals
Business
Cuorips Inc. is a regenerative medicine venture established in 2017, whose core business is the research, development, manufacturing, and sale of the human iPS cell-derived cardiomyocyte sheet "ReHeart®." ReHeart is the world's first iPS cell-derived regenerative medicine product targeting patients with severe heart failure due to ischemic cardiomyopathy who cannot be expected to recover through drug therapy or surgery, and it obtained conditional and time-limited manufacturing and marketing approval from the Ministry of Health, Labour and Welfare in March 2026. Its main customers are medical institutions and hospitals both in Japan and overseas, and in parallel, the company also operates a CDMO business (contract manufacturing of cell products) utilizing "CLiC-1," a commercial cell culture and processing facility located in Minoh City, Osaka Prefecture. Based on industry-academia collaborative alliances with Osaka University, Daiichi Sankyo, Asahi Intecc, and others, the company also holds multiple pipeline projects, including catheter treatments and an in vivo regenerative factor inducer (YS series).
Business Model
Current primary revenue sources are CDMO & Consulting Services (¥210 million of the ¥212 million in net sales for FY2026 (ending March 2026)) and joint R&D expense contributions received from co-development partners (¥336 million in the current fiscal year). Through these, the company has adopted a cash-burn management model that limits its own burden to ¥634 million out of total R&D expenses of ¥970 million. It plans to begin sales of ReHeart® following listing on the drug price list and insurance coverage around autumn 2026, transitioning to a full-scale monetization phase driven by product sales.
Company Strengths
In March 2026, obtained conditional and time-limited manufacturing and marketing approval for "ReHeart®" from the Ministry of Health, Labour and Welfare. In an investigator-initiated clinical trial of 8 cases, all cases were judged "effective," with no adverse events or serious adverse events. In October 2025, it was designated as a regenerative medicine product for rare diseases, making it eligible for a premium in the calculation of the insurance reimbursement price. The company has established a first-mover advantage as the world's first iPS cell-derived cardiomyocyte product.
Since establishing a joint research chair with Osaka University, the company has established technologies for mass culturing, high-purity purification, and removal of undifferentiated cells of iPS cells. It has obtained facility design patents in Japan (Patent No. 7609440), the United States, and Europe. It holds an exclusive license from Osaka University (Patent No. 6938154, valid until November 2035) and an intellectual property license from Daiichi Sankyo, forming a technological barrier to entry.
"CLiC-1," a commercial cell culture processing facility that began operations in August 2020, is a lab-integrated facility capable of handling everything from manufacturing process development to commercial production. It obtained a manufacturing and marketing business license in August 2024 and a manufacturing business license in April 2025. The facility is also utilized for the CDMO business, and CDMO revenue for FY2026 (ending March 2026) totaled ¥210 million (up 25.4% year on year). It has also been selected for the New Technology Introduction Promotion category of the Ministry of Economy, Trade and Industry's "Regenerative Medicine CDMO Subsidy."
ENVALITH's Perspective
Performance Trend
Revenue for FY2026 (ending March 2026) came in at ¥212 million (up 21.2% from ¥175 million in the prior period), securing revenue growth, but cost of sales surged from ¥6 million to ¥82 million, causing gross profit to decline from ¥168 million to ¥130 million. Selling, general and administrative expenses increased substantially to ¥1,212 million (from ¥759 million in the prior period), widening the operating loss to ¥1,081 million (from ¥590 million in the prior period). Total R&D expenses were ¥970 million (down 5.7% year-on-year), but in-house R&D burden after deducting amounts received for joint R&D increased to ¥634 million (up 89.8% year-on-year). Looking at the trend over the past five periods (revenue: ¥38 million → ¥23 million → ¥175 million → ¥212 million; operating loss: ¥450 million → ¥588 million → ¥590 million → ¥1,081 million), revenue has been expanding rapidly since FY2025, but losses also expanded sharply in FY2026. The cash balance at period-end stood at ¥3,900 million (down from ¥4,794 million in the prior period), a decrease of ¥893 million. For FY2027 (ending March 2027), while revenue guidance remains undisclosed, an operating loss of ¥1,430 million is forecast, suggesting the phase of widening losses is expected to continue.
Growth Strategy
Aiming for multi-layered growth through NHI price listing and sales launch based on the domestic approval obtained, together with overseas expansion and strengthening of CDMO operations
Conditional and time-limited manufacturing and marketing approval was obtained in March 2026. NHI price listing is planned for around autumn 2026, with sales expected to commence in the second half. As the product has been designated as an orphan product, it is eligible for premium consideration when calculating the insurance reimbursement price, and preparations for the supply system ahead of the post-marketing surveillance are being advanced.
Collaborative research with Stanford University's Department of Cardiothoracic Surgery has been intensified, with an animal experiment program using myocardial infarction pigs currently underway. General agreement on the development policy, including the First-in-Human trial plan, has been reached at the FDA pre-IND meeting, and preparations for the IND application are proceeding.
Preparations to begin consultations with European regulatory authorities are planned to start in the following fiscal year (FY2027, ending March 2027). Through expansion in Europe in parallel with the US, the company aims to obtain global manufacturing and marketing approval.
Following selection for the Ministry of Economy, Trade and Industry's regenerative medicine CDMO subsidy (New Technology Introduction Promotion Framework), the pilot plant under construction at Nakanoshima Cross is scheduled to begin full-scale operation shortly into the following fiscal year. The company will promote the practical application of a mass culture system through the Value Chain Consortium for Stable Cell Supply Manufacturing (VMaCS), thereby enhancing its contract manufacturing capabilities.
Collaborative research with Osaka University continues, with results accumulating, including the publication of a research paper on cirrhosis. The company is currently in discussions with one overseas pharmaceutical company regarding out-licensing and collaboration, aiming to diversify revenue through out-licensing to pharmaceutical companies.
In collaboration with Asahi Intecc Co., Ltd., a new treatment technology is being developed to transplant human iPS cell-derived cardiomyocytes into the heart via an intravascular approach using a catheter (Catheter (PJ4)). In the following fiscal year, preparations for conducting non-clinical trials are planned to proceed.
Last updated: July 19, 2026